TY - JOUR
T1 - Optimal follow-up to curative colon and rectal cancer surgery
T2 - How and for how long?
AU - Asgeirsson, Theodor
AU - Zhang, Sen
AU - Senagore, Anthony J.
PY - 2010/10/1
Y1 - 2010/10/1
N2 - In 2009, the projected incidence for colon and rectal cancers in the United States was 106,100 and 40,870, respectively, and approximately 75% of these patients were treated with curative intent. Surveillance or follow-up after colon and rectal cancer resection serves multiple purposes; however, the primary argument supporting the validity of surveillance is the detection of metachronous and recurrent cancers amenable to curative treatment. The surveillance may provide some comfort for cancer survivors who can be informed that they have no evidence of disease.
AB - In 2009, the projected incidence for colon and rectal cancers in the United States was 106,100 and 40,870, respectively, and approximately 75% of these patients were treated with curative intent. Surveillance or follow-up after colon and rectal cancer resection serves multiple purposes; however, the primary argument supporting the validity of surveillance is the detection of metachronous and recurrent cancers amenable to curative treatment. The surveillance may provide some comfort for cancer survivors who can be informed that they have no evidence of disease.
KW - Colon cancer
KW - Follow-up
KW - Rectal cancer
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=77957130015&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957130015&partnerID=8YFLogxK
U2 - 10.1016/j.soc.2010.06.003
DO - 10.1016/j.soc.2010.06.003
M3 - Review article
C2 - 20883959
AN - SCOPUS:77957130015
SN - 1055-3207
VL - 19
SP - 861
EP - 873
JO - Surgical Oncology Clinics of North America
JF - Surgical Oncology Clinics of North America
IS - 4
ER -